Brief: Bayer's Sevabertinib Approved In Japan For Patients With Her2-Mutant Non-Small Cell Lung Cancer
24/08/2026 07:31
BRIEF-Bayer's Sevabertinib Approved In Japan For Patients With Her2-Mutant Non-Small Cell Lung Cancer Aug 24 (Reuters) - Bayer AG BAYGn.DE:
SEVABERTINIB APPROVED IN JAPAN FOR PATIENTS WITH HER2-MUTANT NON-SMALL CELL LUNG CANCER
Source text: [ID:]
Further company coverage: BAYGn.DE
((frankfurt.newsroom@thomsonreuters.com;))
Recent news on Bayer AG
See all newsBrief: Bayer Says Finerenone Slowed Kidney Decline In CKD
Insight: How cheap Chinese antibiotics threaten Europe's last major penicillin plant
Deutsche Bank AG FF - Post Stabilisation Notice -Bayer EUR 30NC6 & 30NC9
Brief: Bayer To Present New Finerenone Data Across Chronic Kidney Disease With And Without Diabetes At Asn Kidney Week 2026
Brief: FDA Approves Once-Weekly Generic Hormone Therapy Patch For Women